PL370858A1 - Postacie soli E-2-metoksy-N-(3-{4-[3-metylo-4-(6-metylo-pirydyn-3-yloksy) fenyloamino] chinazolin-6-ylo} allilo)-acetamidu, ich wytwarzanie i ich zastosowanie przeciwrakowe - Google Patents

Postacie soli E-2-metoksy-N-(3-{4-[3-metylo-4-(6-metylo-pirydyn-3-yloksy) fenyloamino] chinazolin-6-ylo} allilo)-acetamidu, ich wytwarzanie i ich zastosowanie przeciwrakowe

Info

Publication number
PL370858A1
PL370858A1 PL02370858A PL37085802A PL370858A1 PL 370858 A1 PL370858 A1 PL 370858A1 PL 02370858 A PL02370858 A PL 02370858A PL 37085802 A PL37085802 A PL 37085802A PL 370858 A1 PL370858 A1 PL 370858A1
Authority
PL
Poland
Prior art keywords
methyl
quinazolin
phenylamino
yloxy
pyridin
Prior art date
Application number
PL02370858A
Other languages
English (en)
Inventor
Daniel Tyler Richter
John Charles Kath
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL370858A1 publication Critical patent/PL370858A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
PL02370858A 2001-12-12 2002-11-11 Postacie soli E-2-metoksy-N-(3-{4-[3-metylo-4-(6-metylo-pirydyn-3-yloksy) fenyloamino] chinazolin-6-ylo} allilo)-acetamidu, ich wytwarzanie i ich zastosowanie przeciwrakowe PL370858A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34088501P 2001-12-12 2001-12-12

Publications (1)

Publication Number Publication Date
PL370858A1 true PL370858A1 (pl) 2005-05-30

Family

ID=23335337

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02370858A PL370858A1 (pl) 2001-12-12 2002-11-11 Postacie soli E-2-metoksy-N-(3-{4-[3-metylo-4-(6-metylo-pirydyn-3-yloksy) fenyloamino] chinazolin-6-ylo} allilo)-acetamidu, ich wytwarzanie i ich zastosowanie przeciwrakowe

Country Status (34)

Country Link
US (1) US6844349B2 (pl)
EP (1) EP1456199A1 (pl)
JP (1) JP4202926B2 (pl)
KR (1) KR20040065259A (pl)
CN (1) CN1608062A (pl)
AP (1) AP2004003059A0 (pl)
AR (1) AR037772A1 (pl)
AU (1) AU2002366581A1 (pl)
BR (1) BR0214876A (pl)
CA (1) CA2469889A1 (pl)
DO (1) DOP2002000544A (pl)
EA (1) EA007412B1 (pl)
EC (1) ECSP045148A (pl)
GE (1) GEP20063872B (pl)
GT (1) GT200200272A (pl)
HR (1) HRP20040530A2 (pl)
HU (1) HUP0402662A2 (pl)
IL (1) IL161915A0 (pl)
IS (1) IS7227A (pl)
MA (1) MA27095A1 (pl)
MX (1) MXPA04005678A (pl)
NO (1) NO20042925L (pl)
NZ (1) NZ532436A (pl)
OA (1) OA12735A (pl)
PA (1) PA8561401A1 (pl)
PE (1) PE20030716A1 (pl)
PL (1) PL370858A1 (pl)
RS (1) RS46404A (pl)
TN (1) TNSN04112A1 (pl)
TW (1) TW200301103A (pl)
UA (1) UA75482C2 (pl)
UY (1) UY27572A1 (pl)
WO (1) WO2003050108A1 (pl)
ZA (1) ZA200402995B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049740A1 (en) * 2001-12-12 2003-06-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
JP4703183B2 (ja) 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． 受容体型キナーゼモジュレーターおよびその使用方法
PL377686A1 (pl) * 2002-12-18 2006-02-06 Pfizer Products Inc. Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek
EP1575936A1 (en) * 2002-12-19 2005-09-21 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
AU2004264726A1 (en) * 2003-08-18 2005-02-24 Pfizer Products Inc. Dosing schedule for erbB2 anticancer agents
AU2004275842B2 (en) 2003-09-26 2010-09-02 Exelixis Inc. c-MET modulators and methods of use
AU2004287416C1 (en) * 2003-10-27 2010-09-09 Merck Sharp & Dohme Corp. CCR-2 antagonist salt
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
WO2005121124A1 (en) * 2004-06-07 2005-12-22 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4-[3-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and methods of preparing same
TR201906416T4 (tr) 2004-07-27 2019-05-21 Gilead Sciences Inc Hiv inhibitörü bileşiklerin fosfonat analogları.
WO2006129163A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
EP1896451A2 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Bicyclic derivatives for the treatment of abnormal cell growth
ES2377467T3 (es) * 2006-05-16 2012-03-27 Gilead Sciences, Inc. Procedimiento y composiciones para tratar enfermedades hematológicas malignas
KR20090090336A (ko) 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
KR20120043775A (ko) * 2006-12-21 2012-05-04 화이자 프로덕츠 인크. 2-((4-(1-메틸-4-(피리딘-4-일)-1ｈ-피라졸-3-일)페녹시)메틸)퀴놀린의 숙시네이트 염
EP2144887A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
JPWO2009113560A1 (ja) 2008-03-12 2011-07-21 武田薬品工業株式会社 縮合複素環化合物
PE20110219A1 (es) 2008-07-08 2011-03-31 Gilead Sciences Inc Sales del compuesto n-[(s)({[(2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il]oxi}metil)fenoxifosfinoil]-l-alaninato de etilo como inhibidores de vih
KR102187034B1 (ko) 2009-01-16 2020-12-04 엑셀리시스, 인코포레이티드 암 치료용 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
JP6914860B2 (ja) 2015-07-01 2021-08-04 カリフォルニア インスティチュート オブ テクノロジー カチオン性粘液酸ポリマー系デリバリーシステム
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP4386967B2 (ja) * 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
CA2413424C (en) * 2000-06-22 2007-10-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
EP1456199A1 (en) 2004-09-15
ECSP045148A (es) 2004-07-23
TW200301103A (en) 2003-07-01
WO2003050108A8 (en) 2003-12-18
HRP20040530A2 (en) 2004-10-31
JP2005511744A (ja) 2005-04-28
MXPA04005678A (es) 2004-12-06
MA27095A1 (fr) 2004-12-20
PE20030716A1 (es) 2003-08-29
NO20042925L (no) 2004-09-07
BR0214876A (pt) 2004-12-28
ZA200402995B (en) 2005-04-20
GEP20063872B (en) 2006-07-10
AU2002366581A1 (en) 2003-06-23
IS7227A (is) 2004-04-19
KR20040065259A (ko) 2004-07-21
EA007412B1 (ru) 2006-10-27
PA8561401A1 (es) 2005-02-04
TNSN04112A1 (fr) 2006-06-01
HUP0402662A2 (hu) 2005-05-30
CN1608062A (zh) 2005-04-20
NZ532436A (en) 2006-01-27
US20030158217A1 (en) 2003-08-21
AP2004003059A0 (en) 2004-06-30
DOP2002000544A (es) 2003-06-16
EA200400674A1 (ru) 2004-10-28
OA12735A (en) 2006-06-29
AR037772A1 (es) 2004-12-01
UY27572A1 (es) 2003-07-31
WO2003050108A1 (en) 2003-06-19
GT200200272A (es) 2003-12-12
UA75482C2 (en) 2006-04-17
IL161915A0 (en) 2005-11-20
RS46404A (en) 2006-10-27
CA2469889A1 (en) 2003-06-19
JP4202926B2 (ja) 2008-12-24
US6844349B2 (en) 2005-01-18

Similar Documents

Publication Publication Date Title
PL370858A1 (pl) Postacie soli E-2-metoksy-N-(3-{4-[3-metylo-4-(6-metylo-pirydyn-3-yloksy) fenyloamino] chinazolin-6-ylo} allilo)-acetamidu, ich wytwarzanie i ich zastosowanie przeciwrakowe
AU2003290973A8 (en) Coating reinforcing underlayment and method of manufacturing same
DE60333066D1 (de) Triterpenoid-haltige Submicronliposomen und ihre Herstellungsweise
IL165386A0 (en) Ceramic anodes and method of producing the same
GB2396332B (en) Slotted substrate and method of making
ZA200504405B (en) Papermaking roll cover and method of its production
PL368637A1 (pl) Związki heterocykliczne i sposoby ich zastosowania
PL376524A1 (pl) Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 i sposób ich wytwarzania
HK1076132A1 (en) Nonwoven fabric and method of manufacture
EP1549674A4 (en) CRYSTAL STRUCTURE OF ERBB2 AND APPLICATIONS THEREOF
AU2003229803A8 (en) Building board and method of fastening one
ATE290530T1 (de) Kristalline hydrate von anilid-derivaten als funigizide und insektizide
PL377533A1 (pl) Kompleksy E-2-metoksy-N-(3-{4-[3-metylo-4-(6-metylopirydyn-3-yloksy)-fenyloamino]-chinazolin-6-ylo}-allilo)-acetamidu, sposób ich wytwarzania i zastosowanie
EP1466596A4 (en) NOVEL MICROSPHERE AND METHOD FOR PRODUCING THE SAME
GB0225255D0 (en) Mine door leaf and method of manufacture thereof
AP2002002602A0 (en) Process for the production of quinazolines
ITFI20010103A0 (it) Metodo ed attrezzatura per la produzione di mattonelle monostrato
GB0301355D0 (en) Production method of polarization maintaining fiber
IL144591A0 (en) Metal alkoxides of baccatin iii and methods for the production thereof
HUP0402368A3 (en) Recovery and recycling of chiral tartaric acid resolving agents
IL152419A0 (en) Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride
TW200611902A (en) Complexes of E-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetami de and methods of preparing same
HK1056483A2 (en) Convertible buildings and method of production thereof
ATE375337T1 (de) Hydrate von gegebenenfalls substituierten 2-(2- pyridinyl)methylthio-1h-benzimidazolen und verfahren zu ihrer herstellung
AU2002349611A1 (en) Ceramic filtering element and method of the production thereof

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)